Skip to main content
Charles Baum, MD, Gastroenterology, Chicago, IL

CharlesBaumMD

Gastroenterology • Chicago, IL

Nutrition, Bariatric Medicine

Physician

Join to view full profile

Dr. Baum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Baum's full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Gastroenterology, 1986 - 1989
  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 1983 - 1986
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1983

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1986 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Gastroenterology

Publications & Presentations

PubMed

Journal Articles

  • Effects of 12 Weeks of Treatment with Intravenously Administered Bococizumab, a Humanized Monoclonal Antibody Blocking Proprotein Convertase subtilisin/kexin Type 9, i...  
    Charles M Baum, Sergio Fazio, Cardiovascular Therapeutics
  • The Effects of Single‐ and Multiple‐Dose Administration of Bococizumab (RN316/PF‐04950615), a Humanized IgG2Δa Monoclonal Antibody Binding Proprotein Convertase subtil...  
    Charles Baum, MD, Cardiovascular Therapeutics

Press Mentions

  • Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
    Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNovember 7th, 2022
  • Mirati's Adagrasib Spurs 41% Response in Pancreatic, GI Tumors, Scoring Points Where KRAS Leader Amgen Hasn't Gone
    Mirati's Adagrasib Spurs 41% Response in Pancreatic, GI Tumors, Scoring Points Where KRAS Leader Amgen Hasn't GoneJanuary 21st, 2022
  • Mirati Gives First Look at KRAS Drug Combination in Lung Cancer
    Mirati Gives First Look at KRAS Drug Combination in Lung CancerNovember 8th, 2021
  • Join now to see all

Industry Relationships

  • Vice President, TakedaHead of US medical and scientific affairs2006 - 2015

Dr. Charles Baum, Dr. Charles Baum, MD, Dr. C Baum